These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27834954)

  • 21. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
    Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
    Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
    Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
    Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
    Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
    Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hsp90 and the Fanconi anemia pathway: a molecular link between protein quality control and the DNA damage response.
    Yamashita T; Oda T; Sekimoto T
    Cell Cycle; 2007 Sep; 6(18):2232-5. PubMed ID: 17881891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
    Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
    Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
    Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
    Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 18β-glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway.
    Yang JC; Myung SC; Kim W; Lee CS
    Mol Cell Biochem; 2012 Nov; 370(1-2):209-19. PubMed ID: 22865487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
    Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
    Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin.
    Bagatell R; Beliakoff J; David CL; Marron MT; Whitesell L
    Int J Cancer; 2005 Jan; 113(2):179-88. PubMed ID: 15455381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90).
    Brasca MG; Mantegani S; Amboldi N; Bindi S; Caronni D; Casale E; Ceccarelli W; Colombo N; De Ponti A; Donati D; Ermoli A; Fachin G; Felder ER; Ferguson RD; Fiorelli C; Guanci M; Isacchi A; Pesenti E; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Fogliatto G
    Bioorg Med Chem; 2013 Nov; 21(22):7047-63. PubMed ID: 24100158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.
    Lai CH; Park KS; Lee DH; Alberobello AT; Raffeld M; Pierobon M; Pin E; Petricoin Iii EF; Wang Y; Giaccone G
    Oncogene; 2014 Oct; 33(40):4867-76. PubMed ID: 24166505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1.
    Liu E; Liu Z; Zhou Y
    Int J Clin Exp Pathol; 2015; 8(4):3803-10. PubMed ID: 26097562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
    Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
    Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling.
    Lee H; Saini N; Parris AB; Zhao M; Yang X
    Int J Oncol; 2017 Sep; 51(3):967-974. PubMed ID: 28713919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.
    Lock RB; Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Jul; 60(7):E42-5. PubMed ID: 23303741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ganetespib synergizes with cyclophosphamide to improve survival of mice with autochthonous tumors in a mutant p53-dependent manner.
    Alexandrova EM; Xu S; Moll UM
    Cell Death Dis; 2017 Mar; 8(3):e2683. PubMed ID: 28300840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.